Akeso, Inc. (HKG:9926)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
84.35
+0.10 (0.12%)
May 9, 2025, 4:08 PM HKT

Akeso Company Description

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of antibody drugs.

The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.

It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, PD-1, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, PD-L1 for the treatment of recurrent or metastatic NPC.

In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis.

Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.

Akeso, Inc.
Country Cayman Islands
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 2,778
CEO Yu Xia

Contact Details

Address:
No. 6, Shennong Road
Zhongshan, 528437
China
Phone 86 76 0898 73998
Website akesobio.com

Stock Details

Ticker Symbol 9926
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG0146B1032
SIC Code 2836

Key Executives

Name Position
Dr. Yu Xia Ph.D. Founder, Chief Executive Officer, President and Chairwoman
Dr. Baiyong Li Ph.D. Co-Founder, Executive Vice President, CSO and Executive Director
Zhongmin Wang Ph.D. Co-Founder, Senior Vice President and Executive Director
Dr. Bing C. Wang M.B.A., Ph.D. Chief Financial Officer
Dr. Xinfeng Zhang Senior Vice President
Dr. Mingxiu Hu Ph.D. Senior Vice President
Dr. Charlie Zhang Ph.D. Senior Vice President
Dr. Jing Min Ph.D. Senior Vice President
Yong Guo Senior Vice President and Chief Commercial Officer
Wai Yan Leung Company Secretary